Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
MYCB1 Group B.V. logo — MYCB1 Group B.V. produces, and distributes GMP-grade cannab...

MYCB1 Group B.V.

MYCB1 Group B.V. produces, and distributes GMP-grade cannabinoid medicines via its German subsidiary, MYCB1 GmbH

Founded 2017 The Netherlands The Netherlands 18 employees Debt Financing Total: $3.11M AI, Health Care +2

General Information

Company Name MYCB1 Group B.V.
Founded Year 2017
Location The Netherlands The Netherlands +2
Employees 18
Industries AI, Health Care, Medical Devices +1
Funding Stage Debt Financing
Social

Get notified when MYCB1 Group B.V. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About MYCB1 Group B.V.

MYCB1 Group B.V. is a Dutch pharmaceutical group that stands out for its specialization in cannabinoid-based medical solutions. Its subsidiary, MYCB1 GmbH in Steinheim, Westphalia, serves as the core of its operations, focusing on the production and distribution of GMP-grade cannabinoid medicines.

Founded in 2017, MYCB1 Group B.V. operates within a diverse range of industries including AI, Health Care, Medical Devices, and Pharmaceutical. The company leverages its expertise to develop prescription-only medications that cater to a global market.

Headquartered in The Netherlands, the company last secured a financing round of €250.00K through debt financing on 01 October 2021. Despite the lack of specific investor names, this financial backing could illustrate investor confidence in their innovative approach to cannabinoid therapeutics.

Taxonomy: Cannabinoid Medicines, GMP-grade Pharmaceuticals, Pharmaceutical Manufacturing, Prescription-only Medications, Personalized Medicine, Digital Health Solutions, Generative AI, Real-World Evidence, Patient-Centric Healthcare, Data-Driven Health Decisions, Health Technology Scale-up, Evidence-Based Healthcare, Software Engineering in Health, Pharmacy Operations

Services & Products

regulatory infrastructure support
GMP/GDP operations
storage services
distribution services
brand retention services
curated product portfolio

Target Customers

pharmaceutical companies cannabis brands healthcare distributors

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing •••••• - 01 Oct 2021
Funding Round •••••• - 01 Mar 2021
Non Equity Assistance •••••• - 01 Jan 2020

MYCB1 Group B.V. Alternatives & Competitors

View All Alternatives
MYCB1 Group B.V. vs
Opticann
Opticann

Delivering advanced cannabinoid solutions for maximum absorption and stability through innovative dr...

Health Care
MYCB1 Group B.V. vs
BresMed
BresMed

Offering innovative health economic solutions for the global pharmaceutical industry

Biotechnology, Health Care
MYCB1 Group B.V. vs
Evidera
Evidera United States

Evidera, a PPD business specializing in evidence, value, and access

574 employees
Analytics, Health Care
View all alternatives

FAQ About MYCB1 Group B.V.

MYCB1 Group B.V. produces, and distributes GMP-grade cannabinoid medicines via its German subsidiary, MYCB1 GmbH
MYCB1 Group B.V. was founded in 2017.
MYCB1 Group B.V. is headquartered in The Netherlands.
MYCB1 Group B.V. operates in the following industries: AI, Health Care, Medical Devices, Pharmaceutical.
MYCB1 Group B.V. has approximately 18 employees.
MYCB1 Group B.V. has completed 3 funding rounds, raising a total of $3.11M. The latest funding stage is Debt Financing.
MYCB1 Group B.V. offers: regulatory infrastructure support, GMP/GDP operations, storage services, distribution services, brand retention services, curated product portfolio.
Top alternatives and competitors to MYCB1 Group B.V. include Opticann, BresMed, Evidera, Pharmed Limited, Certified Brands Group. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MYCB1 Group B.V. and Opticann are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors MYCB1 Group B.V. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy